Ozempic

News

China delivers a win for Novo Nordisk on semaglutide IP

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.

News

Novo Nordisk cuts Wegovy price ahead of TrumpRx launch

Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.

News

Company representatives with President Trump in the Oval Office

Novo, Lilly sign MFN pricing deal with Trump administration

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

Novo Nordisk's new chief executive Mike Doustdar

Novo Nordisk cuts guidance again on weaker GLP-1 growth

Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.

News

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

China delivers a win for Novo Nordisk on semaglutide IP

Novo Nordisk cuts Wegovy price ahead of TrumpRx launch

Novo, Lilly sign MFN pricing deal with Trump administration

Novo Nordisk cuts guidance again on weaker GLP-1 growth

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk weakens again on interim results readout

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Ozempic

Editor's Picks